Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from January 8, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 8, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$111.25 Published $122.38 Target $123.18 Window close $125.14 Peak
$107.00 – $112.00Entry zone — fair-value band
$111.25Published — price the day we called it
$122.38Target — the price the thesis aimed for
$125.14Peak — highest point inside the window, not a realized return
$123.18Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 28 days.

Peak price
$125.14
peak on February 25, 2026 — not a realized return
Peak gain
+12.5%
peak, from the publication price
Window close
$123.18
end-of-window price, context only
Days to target
28
Window
January 8, 2026 – April 8, 2026

The thesis — published January 8, 2026

Predicted growth
+10%
over the measurement window
Target price
$122.38
the price the thesis aimed for
Entry zone
$107.00 – $112.00
the fair-value band we waited for
Price at publication
$111.25
published January 8, 2026
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck looks like a short-term defensive growth pick because two recent events could draw attention: an analyst upgrade with a higher price target and the start of a Phase 3 lung cancer trial with calderasib plus Keytruda. Those can bring more buyers, but the stock has already risen, so wait for a pullback before buying.

Primary drivers

  • Analyst upgrade may attract more institutional buyers
  • Phase 3 trial start creates news and interest
  • Works as defensive pharma exposure if markets turn cautious
  • Recent run raises chance of a short-term pullback; wait to enter

How it played out

MRK: target reached in 28 days

Lyra published MRK at $111.25 on January 8, 2026, with a short-term thesis for 10% growth. The thesis pointed to an analyst upgrade, the start of a Phase 3 lung cancer trial with calderasib plus Keytruda, defensive pharma exposure, and the risk that a recent run could bring a pullback before entry.

Inside the window, MRK reached the $122.38 target in 28 days. It peaked at $125.14 on February 25, a 12.5% gain, and ended the window at $123.18. The published thesis played out. The target was reached, and the closing price stayed above it.

What happened during the window

On February 3, 2026, Merck reported fourth-quarter revenue of $16.4 billion and adjusted earnings of $2.04 per share. It also gave 2026 guidance for revenue of $65.5 billion to $67 billion and adjusted earnings of $5.00 to $5.15 per share.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals